Teva bids to stop the rot with growth strategy

Famed as a great success story of the generics sector in previous decades, Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) has seen its growth and share price tail off since the mid-2010s.

But the company is attempting to reverse this and has now announced a new strategy, called Pivot to Growth, as it bids to return to profit and greater impact on the lives of patients.

This new strategic framework contains four main pillars to position the company for a new era of growth, the first being accelerating the firm’s commercial portfolio comprising Austedo (deutetrabenazine), a treatment for both tardive dyskinesia and Huntington's disease chorea, the migraine drug Ajovy (fremanezumab), schizophrenia therapy Uzedy (risperidone) and the company’s biosimilar offerings.